SMW Free Realtime Trade Alerts -- Our Last 2 Trade Alerts were VII and NFEC, easy 40-75% wins in minutes, Join Today for FREE!!

Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading RNA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.96%88.251.6%$793.99m
BIIBBiogen Inc.
0.90%290.361.2%$588.85m
CELGCelgene Corporation
0.41%107.961.1%$491.51m
AMGNAmgen Inc.
0.30%166.161.2%$490.02m
REGNRegeneron Pharmaceuticals, Inc.
0.41%392.933.1%$325.29m
ALXNAlexion Pharmaceuticals, Inc.
1.63%127.862.6%$294.57m
TSROTESARO, Inc.
-0.95%91.1218.0%$213.64m
BMRNBioMarin Pharmaceutical Inc.
-0.03%93.553.9%$197.24m
ILMNIllumina, Inc.
-0.46%150.065.1%$187.30m
MDVNMedivation, Inc.
-0.33%62.432.6%$145.05m
VRTXVertex Pharmaceuticals Incorporated
2.31%96.061.7%$135.72m
JUNOJuno Therapeutics, Inc.
0.96%29.417.9%$107.13m
AAgilent Technologies, Inc.
-1.03%46.101.9%$99.83m
INCYIncyte Corporation
-0.36%86.102.2%$86.98m
ACADACADIA Pharmaceuticals Inc.
-0.64%36.3213.1%$78.66m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.